CD34 and therapy-related myeloid neoplasm: When studying baseline clinical determinants of tMN development (Supplementary Table S6), our cox proportional hazards model showed that the risk of tMN is independently influenced by age ≥ 60 years at the time of aHSCT (HR 2.5, 95% CI 1.2–5.3), male sex (HR 6.3, 95% CI 1.9–20.9), graft cellularity (CD34+ dose < 3.0 × 106/Kg; HR 2.5, 95% CI 1.5–5.5), high pre-aHSCT treatment burden ( ≥ 3 lines of chemotherapy; HR 4.7, 95% CI 2.2–10.0), and prior radiation (HR 5.2, 95% CI 2.5–10.9; Fig. 2A; Supplementary Table S7).